13 Breast Cancer Clinical Trials in Beverly Hills, CA (2026)

Q: How do I join a clinical trial in Beverly Hills?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Beverly Hills research site will contact you.

Recruiting Breast Cancer Studies in Beverly Hills

NCT05774951Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk f...

Beverly Hills, CAPHASE34,300 participantsAstraZeneca

View Study Details

NCT06492616Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal G...

Beverly Hills, CAPHASE34,220 participantsStemline Therapeutics, Inc.

View Study Details

NCT06058377Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-I...

Beverly Hills, CAPHASE33,680 participantsNational Cancer Institute (NCI)

View Study Details

NCT06876714Recruiting

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in...

Beverly Hills, CAPHASE31,524 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT05827081Recruiting

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on in...

Beverly Hills, CAPHASE31,400 participantsNovartis Pharmaceuticals

View Study Details

NCT07085767Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for...

Beverly Hills, CAPHASE31,000 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT06982521Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER...

Beverly Hills, CAPHASE3540 participantsRelay Therapeutics, Inc.

View Study Details

NCT06072612Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physi...

Beverly Hills, CAPHASE3404 participantsBriaCell Therapeutics Corporation

View Study Details

NCT06827236Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participan...

Beverly Hills, CAPHASE1380 participantsBioNTech SE

View Study Details

NCT06113016Recruiting

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as...

Beverly Hills, CAPHASE2164 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT06369285Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-n...

Beverly Hills, CAPHASE2150 participantsPuma Biotechnology, Inc.

View Study Details

NCT05595499Recruiting

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance...

Beverly Hills, CAPHASE288 participantsJonsson Comprehensive Cancer Center

View Study Details

NCT06075810Recruiting

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable....

Beverly Hills, CAPHASE148 participantsMBQ Pharma

View Study Details

About Breast Cancer Clinical Trials in Beverly Hills

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 13 breast cancer clinical trials recruiting participants in Beverly Hills, CA. These studies are seeking a combined 17,898 participants. Research is being sponsored by AstraZeneca, Stemline Therapeutics, Inc., National Cancer Institute (NCI) and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Beverly Hills — FAQ

Are there breast cancer clinical trials in Beverly Hills?

Yes, there are 13 breast cancer clinical trials currently recruiting in Beverly Hills, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Beverly Hills?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beverly Hills research site will contact you about next steps.

Are clinical trials in Beverly Hills free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beverly Hills studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 13 active trials in Beverly Hills are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 17, 2026 from ClinicalTrials.gov